Zobrazeno 1 - 10
of 246
pro vyhledávání: '"Stephen T. Keir"'
Autor:
Seethalakshmi Hariharan, Benjamin T. Whitfield, Christopher J. Pirozzi, Matthew S. Waitkus, Michael C. Brown, Michelle L. Bowie, David M. Irvin, Kristen Roso, Rebecca Fuller, Janell Hostettler, Sharvari Dharmaiah, Emiley A. Gibson, Aaron Briley, Avani Mangoli, Casey Fraley, Mariah Shobande, Kevin Stevenson, Gao Zhang, Prit Benny Malgulwar, Hannah Roberts, Martin Roskoski, Ivan Spasojevic, Stephen T. Keir, Yiping He, Maria G. Castro, Jason T. Huse, David M. Ashley
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional imm
Externí odkaz:
https://doaj.org/article/93956c3a4d2c4721a96aa5db55f8df28
Autor:
Ryan T. Bushey, M. Anthony Moody, Nathan L. Nicely, Barton F. Haynes, S. Munir Alam, Stephen T. Keir, Rex C. Bentley, Kingshuk Roy Choudhury, Elizabeth B. Gottlin, Michael J. Campa, Hua-Xin Liao, Edward F. Patz, Jr.
Publikováno v:
Cell Reports, Vol 15, Iss 7, Pp 1505-1513 (2016)
Summary: Some patients with cancer never develop metastasis, and their host response might provide cues for innovative treatment strategies. We previously reported an association between autoantibodies against complement factor H (CFH) and early-stag
Externí odkaz:
https://doaj.org/article/cbbb0def8add473189d0d67f64d632aa
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
Autor:
Xin Yu, Mikhail Dobrikov, Stephen T Keir, Matthias Gromeier, Ira H Pastan, Ralph Reisfeld, Darell D Bigner, Vidyalakshmi Chandramohan
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210608 (2019)
Standard treatment, unfortunately, yields a poor prognosis for patients with primary or metastatic cancers in the central nervous system, indicating a necessity for novel therapeutic agents. Immunotoxins (ITs) are a class of promising therapeutic can
Externí odkaz:
https://doaj.org/article/9cf75c38d06a465c995844ad4ebb2572
Autor:
Seethalakshmi Hariharan, Benjamin T. Whitfield, Christopher J. Pirozzi, Matthew S. Waitkus, Michael C. Brown, Michelle L. Bowie, David M. Irvin, Kristen Roso, Rebecca Fuller, Janell Hostettler, Sharvari Dharmaiah, Emiley A. Gibson, Aaron Briley, Avani Mangoli, Casey Fraley, Mariah Shobande, Kevin Stevenson, Gao Zhang, Prit Benny Malgulwar, Hannah Roberts, Martin Roskoski, Ivan Spasojevic, Stephen T. Keir, Yiping He, Maria G. Castro, Jason T. Huse, David M. Ashley
Publikováno v:
bioRxiv
Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations inATRX, defining molecular alterations inIDH-mutant astrocytomas, have been implicated in dysfunctional immune signali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ab341a30e4ab8c2358affae1c167fe
https://europepmc.org/articles/PMC10153255/
https://europepmc.org/articles/PMC10153255/
Autor:
David M. Ashley, Gao Zhang, Kalil Abdullah, Jerry W. Shay, Kongming Wu, Lunxu Liu, Keith Flaherty, Stephen T. Keir, Zhi Wei, Utz Herbig, Gordon Mills, Meenhard Herlyn, Yiling Lu, Kyle M. Walsh, Mustafa Khasraw, Edward Pan, Roger E. McLendon, Wen Jiang, Matthew Waitkus, Seethalakshmi Hariharan, Michelle Bowie, Eric Sugarman, Casey M. Charbonneau, Marilyne Labrie, Yaohui Chen, Meng Tian, Hao Liu, Di Wu, Yin Ku, Zachary J. Reitman, Themistoklis Vasilopoulos, Silvia Siteni, Ilgen Mender, Kuang Du, Xiang Lin, Milan Savani, Shiyou Wei, Shengnan Yu
Supplementary Figure 1. (A-B) Successful labeling of CellTrace Violet for M059K and H4 cells. M059K and H4 cells were labeled with a cell membrane dye CellTrace Violet and verified the success of labeling by FACS. (C-D) Cell viability of M059K and H4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b67de367e12ada341397828d118d525
https://doi.org/10.1158/1078-0432.22483260.v1
https://doi.org/10.1158/1078-0432.22483260.v1
Autor:
Malcolm A. Smith, Larry Rubinstein, Catherine A. Billups, Amy W. Wozniak, Jianrong Wu, E. Anders Kolb, Stephen T. Keir, John M. Maris, Min H. Kang, C. Patrick Reynolds, Hernan Carol, Richard B. Lock, Richard Gorlick, Christopher L. Morton, Peter J. Houghton
Rapamycin demonstrated broad-spectrum tumor growth inhibition activity against the in vivo panels of childhood tumors used in the Pediatric Preclinical Testing Program (PPTP). Here we have evaluated rapamycin combined with agents used frequently in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46a05733570a040613b655bf2870d0be
https://doi.org/10.1158/1535-7163.c.6531555.v1
https://doi.org/10.1158/1535-7163.c.6531555.v1
Autor:
David M. Ashley, Gao Zhang, Kalil Abdullah, Jerry W. Shay, Kongming Wu, Lunxu Liu, Keith Flaherty, Stephen T. Keir, Zhi Wei, Utz Herbig, Gordon Mills, Meenhard Herlyn, Yiling Lu, Kyle M. Walsh, Mustafa Khasraw, Edward Pan, Roger E. McLendon, Wen Jiang, Matthew Waitkus, Seethalakshmi Hariharan, Michelle Bowie, Eric Sugarman, Casey M. Charbonneau, Marilyne Labrie, Yaohui Chen, Meng Tian, Hao Liu, Di Wu, Yin Ku, Zachary J. Reitman, Themistoklis Vasilopoulos, Silvia Siteni, Ilgen Mender, Kuang Du, Xiang Lin, Milan Savani, Shiyou Wei, Shengnan Yu
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a7426631ce3a265093a1f02348bfc5
https://doi.org/10.1158/1078-0432.22483269
https://doi.org/10.1158/1078-0432.22483269
Autor:
Darell D. Bigner, Ira H. Pastan, Chien-Tsun Kuan, Roger E. McLendon, Carol J. Wikstrand, Hailan Piao, Scott E. Szafranski, Charles N. Pegram, Stephen T. Keir, Xuhui Bao, Vidyalakshmi Chandramohan
Supplementary Figure Legends - PDF file 88K, Supplementary Figure Legends 1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d57827a40d5e97fa0f84d6dc15d4368d
https://doi.org/10.1158/1078-0432.22447890.v1
https://doi.org/10.1158/1078-0432.22447890.v1
Autor:
David M. Ashley, Gao Zhang, Kalil Abdullah, Jerry W. Shay, Kongming Wu, Lunxu Liu, Keith Flaherty, Stephen T. Keir, Zhi Wei, Utz Herbig, Gordon Mills, Meenhard Herlyn, Yiling Lu, Kyle M. Walsh, Mustafa Khasraw, Edward Pan, Roger E. McLendon, Wen Jiang, Matthew Waitkus, Seethalakshmi Hariharan, Michelle Bowie, Eric Sugarman, Casey M. Charbonneau, Marilyne Labrie, Yaohui Chen, Meng Tian, Hao Liu, Di Wu, Yin Ku, Zachary J. Reitman, Themistoklis Vasilopoulos, Silvia Siteni, Ilgen Mender, Kuang Du, Xiang Lin, Milan Savani, Shiyou Wei, Shengnan Yu
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::870c47a2d8ebe7eeca098bdd8af9a32a
https://doi.org/10.1158/1078-0432.22483272.v1
https://doi.org/10.1158/1078-0432.22483272.v1
Autor:
Peter J. Houghton, Richard B. Lock, Malcolm A. Smith, Nana Boateng, Catherine A. Billups, Jianrong Wu, Igor Dvorchik, Raushan T. Kurmasheva, Stephen T. Keir, Min H. Kang, C. Patrick Reynolds, Richard Gorlick, E. Anders Kolb, John M. Maris, Han Yin, Brendan Murphy
Traditional approaches to evaluating antitumor agents using human tumor xenograft models have generally used cohorts of 8 to 10 mice against a limited panel of tumor models. An alternative approach is to use fewer animals per tumor line, allowing a g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c6509d5f93e639d8d6f7068b6cdc5f
https://doi.org/10.1158/0008-5472.c.6508796.v1
https://doi.org/10.1158/0008-5472.c.6508796.v1